CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Ultragenyx to sell FDA priority review voucher for $210M

Positive
AI Analysis

Summary

Ultragenyx Pharmaceutical is selling an FDA priority review voucher for $210 million, generating capital from the valuable regulatory asset.

Importance:5/10
Sentiment:
0.50
priority review vouchercapital raiseFDA
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on October 7, 2026 2:09 PM

Read Original